 MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced dosing of the first patient of the Phase 1 IMMUNICY-1 trial of CYAD-211, the Companys novel, short hairpin RNA shRNA-based anti-B-cell maturation antigen BCMA candidate for the treatment of relapsedrefractory multiple myeloma rr MM. 